ClinicalTrials.gg
RecruitingNCT06718270Updated Dec 12, 2024

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

An Early Phase 1 interventional study of CAR-T cells Infusion in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia, sponsored by Shanghai Changzheng Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Primary conditionLeukemia, Plasma CellRegistry: Multiple MyelomaReclassifiedWhy we changed it
Registry
Multiple Myeloma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Plasma Cell
Why
  1. The study's listed conditions name Leukemia, Plasma Cell, a narrower term within Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Changzheng Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Plasma Cell with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Leukemia, Plasma Cell · China.

Planned enrollment
8th of 19
24 · median 24
Started
2024
the only one that year
Phase 1
7 of 20
7 open now
Primary completion
2027-01
later than 7 of 17 live
Registered
11th of 20
by date

Among the 20 studies in Leukemia, Plasma Cell with a site in China, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 7 in phase 1, reaches primary completion later than 7 of the 17 other live ones, and was the 11th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

17 of the 20 studies in Leukemia, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm, open-label, exploratory dose-escalation and dose-finding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with R/R MM and PCL.RRMM and RRpPCL

Read the detailed description

This study is a single-arm, open-label, exploratory dose-escalation and dose-finding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with R/R MM and PCL.RRMM and RRpPCL.

During the trial, dose increases or decreases or dose expansion may be performed using i3+3 principle based on the safety and ,tolerability and PK data of the patients.

All Patients will undergo a DLT assessment period which is defined as the first 28 days starting from the day of CT0596 infusion. A patient is evaluable for DLTs if the patient received the planned CT0596 dose and either completed the 28 days of DLT evaluation period after CT0596 infusion or experienced a DLT. Enrolled patients who are not evaluable for DLTs during dose escalation may be replaced. Any Patients who are not DLT evaluable will still be followed for safety and efficacy per the SOA.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma
  • Relapsed/Refractory Plasma Cell Leukemia

Browse trials for

Keywords

  • Relapsed/Refractory Multiple Myeloma
  • Relapsed or Refractory Plasma Cell Leukemia
  • CAR-T
04

In context

Leukemia, Plasma Cell Reclassified

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

This study's planned enrollment of 24 is below the median of 27 across 53 interventional studies indexed under Leukemia, Plasma Cell.

Browse Leukemia, Plasma Cell studies →

Lead sponsor

Shanghai Changzheng Hospital is the lead sponsor of 128 studies on the registry; 60 are open to participants now.

Compared within Leukemia, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Myeloma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be enrolled:

  1. Patients must voluntarily sign the form (ICF) and must be willing and be able to adhere to the trial visit schedule and other protocol requirements and agree to be in long term follow-up (LTFU) for up to 15 years as mandated by the regulatory guidelines.
  2. Age ≥ 18 years;
  3. Patients with R/RMM who have received at least 3 , including at least 1 proteasome inhibitor and at least 1 immunomodulator (IMiD). Patients with RRpPCL had received at least 1 prior line of therapy. Number of lines of therapy was defined according to the guidelines provided in Rajkuma[1]r 2015 . Patients must have received at least 1 complete cycle of therapy for each line of therapy.
  4. According to multiple myeloma IMWG 2016 and plasma cell leukemia IMWG 2013, patients must have progressive disease following or during the last treatment.
  5. Patients must have based on at least one of the following parameters:
  6. Expected survival > 12 weeks;
  7. (ECOG) score 0- 1 ;
  8. Patients should meet the following test results
  9. Female patients of must have a negative pregnancy test at screening and prior to receiving lymphodepletion therapy and are willing to use a highly effective and reliable method of for 1 year after receiving study treatment and are absolutely prohibited from donating eggs for 1 year after receiving study treatment infusion during the study ;Male patients are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment if they are sexually active with a female of childbearing potential. Sperm donation is absolutely prohibited within 1 year following study treatment infusion for all male patients during the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Patient has any significant condition(s), laboratory abnormality or psychiatric illness that would impair the ability of the patient to receive or tolerate the planned treatment or in the opinion of the investigator, participation would not be in the best interest of the patient (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  3. Patients seropositive for , active virus (HCV), or active virus (HBV) infection. History of treated hepatitis B or C is permitted if the viral load is undetectable per qPCR and or nucleic acid testing;
  4. Patients with any uncontrolled active infection, including but not limited to patients with active tuberculosis (investigator 's judgment);
  5. Toxicities caused by previous treatment have not recovered to (CTCAE) ≤ Grade 1, except alopecia and other events that are judged tolerable by the investigator;
  6. Previous stem cell transplantation; autologous stem cell transplantation within 12 weeks prior to signing ;
  7. Have received treatment for the disease within 14 days before informed consent
  8. Have received cell therapy within 28 days before informed consent.
  9. Systemic equivalent to > 15 mg/day prednisone within 7 days prior to informed consent, with the exception of topical glucocorticoids;
  10. Vaccination with , inactivated vaccines or RNA vaccines within 4 weeks prior to informed consent;
  11. Allergic or intolerant to lymphodepletion, tocilizumab, or allergic to components (DMSO) in CT0596 CART cell infusion preparation; or previous history of other serious allergies such as anaphylactic shock;
  12. Patients Waldenström macroglobulinemia, POEMS syndrome, or primary light chain amyloidosis at Screening;
  13. Patients with any of the following cardiac conditions within 6 months prior to screening:
  14. Patients who require supplemental oxygen to maintain oxygen saturation > 92%; or Patients with known or suspected who have (FEV1) \< 50% of predicted normal on spirometry;
  15. Patients with active diseases, including but not limited to psoriasis, rheumatoid arthritis and other diseases requiring long-term therapy;
  16. Patients with second primary are not eligible if the second primary malignancy has required treatment within the past 2 years or is not in complete remission. Exceptions include the following that have been successfully treated - nonmetastatic basal cell or squamous cell skin carcinoma, non- prostate cancer, carcinoma-in-situ of breast or cervix, non-muscle invasive bladder cancer
  17. Patients with symptomatic central nervous system (CNS) disease or suspected ;
  18. Major surgery within 2 weeks before informed consent or planned during the study period or within 4 weeks after giving study treatment (excluding local anesthesia such as cataract)
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    CAR-T cells Infusion

    chimeric antigen receptor T cells

    Drug: CAR-T cells Infusion

Interventions

07

What researchers measure

Primary outcomes

  1. Adverse Events (AE) after CT0596 infusion

    An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria

    Time frame: 12 months after CT0596 infusion

  2. MTD and/or dose range

    Evaluate Dose limited toxicity and recommended dosage range after CT0596 infusion

    Time frame: 12 months after CT0596 infusion

Secondary outcomes

  1. Overall response rate (ORR) as assessed by the investigator

    Overall response rate (ORR) defined as proportion of patients achieving partial response or better based on International Myeloma Working Group defined response criteria

    Time frame: 12 months after CT0596 infusion

  2. Complete response/stringent complete response (CR/sCR) rate

    Rate of complete response/stringent complete response (CR/sCR) defined as proportion of patients achieving CR or better based on IMWG defined response criteria.

    Time frame: 12 months after CT0596 infusion

  3. Rate of very good partial response (VGPR) and above

    Rate of complete very good partial response response/stringent complete response (VGPR/CR/sCR) defined as proportion of patients achieving VGPR or better based on IMWG defined response criteria

    Time frame: 12 months after CT0596 infusion

  4. Duration of response (DOR)

    DOR is defined as the time from first achieving PR or better to confirmed disease progression or death from any cause

    Time frame: 12 months after CT0596 infusion

  5. Minimal residual disease (MRD) negative rate

    Minimal residual disease (MRD) negative rate is defined as the proportion of patients with VGPR or better who achieved 10-5 sensitivity of nucleated cell

    Time frame: 12 months after CT0596 infusion

  6. Time to response (TTR)

    TTR defined as the time from the date of apheresis to the date of initial assessment of PR or better according to IMWG2016 criteria

    Time frame: 12 months after CT0596 infusion

  7. Progression-free survival (PFS)

    PFS defined as the time from the date of apheresis of the subject to the first assessment of confirmed disease progression or death from any cause according to IMWG2016 criteria, whichever occurs first.

    Time frame: 12 months after CT0596 infusion

  8. Peak value of CART cells

    Time to peak expansion and peak expansion in plasma after infusion of CT0596 cells

    Time frame: 12 months after CT0596 infusion

  9. Overall survival (OS)

    OS defined as the time from the date of apheresis of the subject to death from any cause

    Time frame: 12 months after CT0596 infusion

  10. Cytokines in the peripheral blood after CT0596 infusion

    Serum concentrations of interleukin (IL)-6 after CT0596 infusion

    Time frame: 12 months after CT0596 infusion

  11. Area under the plasma concentration versus time curve (AUC) of CART cells

    Area under the plasma concentration versus time curve (AUC) in plasma after infusion of CT0596 cells

    Time frame: 12 months after CT0596 infusion

  12. In vivo persistence of CART cells

    CART cells duration in plasma after infusion of CT0596 cells

    Time frame: 12 months after CT0596 infusion

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2024
First posted
Dec 5, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Jan 3, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06718270
Collaborators
CARsgen Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Dec 11, 2024
Primary completion
Jan 3, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 12, 2024

Study contacts

Juan Du, Ph D
Contact
juan_du@live.com
15800706091
Juan Du, Ph D
principal investigator · Shanghai Changzheng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion